AbbVie | ABBV - Operating Expenses


AbbVie reported $10.27B in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Abbott USD 10.46B 1.15B Jun/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eisai JPY 209.6B 6.14B Jun/2026
Eli Lilly USD 10.02B 285M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
J&J USD 17.83B 388M Jun/2026
Medtronic USD 7.72B 436M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Pacira USD 172.75M 20.93M Mar/2026
Perrigo USD 935.6M 89.6M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
UCB EUR 2.96B 196M Dec/2025
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026
Zoetis USD 3.23B 1.68B Mar/2026